» Articles » PMID: 1699491

Direct Comparisons of Inhibitor Sensitivities of Reverse Transcriptases from Feline and Human Immunodeficiency Viruses

Overview
Specialty Pharmacology
Date 1990 Aug 1
PMID 1699491
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The sensitivities of reverse transcriptases (RTs) from feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV) were directly compared. The two enzymes had similar sensitivities to three analogs of dTTP, namely, 3'-azido-3'-deoxythymidine 5'-triphosphate, 2',3'-dideoxythymidine 5'-triphosphate, and 2',3'-dideoxy-2',3'-didehydrothymidine 5'-triphosphate. Each of these analogs demonstrated competitive inhibition of both enzymes. Ki values for inhibition of FIV RT by these three inhibitors were 3.3, 6.7, and 1.8 nM, respectively; Ki values for inhibition of the HIV enzyme were 6.5, 5.9, and 8.3 nM, respectively. Ratios of the Ki for the inhibitor to the Km for the substrate were also determined for each inhibitor, and no differences between the two enzymes greater than threefold were observed. Inhibition constants for 3'-amino-3'-deoxythymidine 5'-triphosphate and 3'-fluoro-3'-deoxythymidine 5'-triphosphate were determined for FIV RT, and these were similar to published values for HIV RT. The activities of three dideoxynucleoside 5'-triphosphates against FIV RT were determined; ddGTP was slightly more potent than ddTTP, whereas both were much more effective than ddCTP. The activity of a noncompetitive inhibitor, phosphonoformate, was also examined with the FIV enzyme; it was much more active with poly(rA)-oligo(dT) as the template-primer than with poly(rC)-oligo(dG) or poly(rI)-oligo(dC).

Citing Articles

Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.

Jordan H, Pereira A, Cohen M, Kashuba A Antimicrob Agents Chemother. 2001; 45(7):2173-6.

PMID: 11408248 PMC: 90625. DOI: 10.1128/AAC.45.7.2173-2176.2001.


A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Smith R, Klarmann G, Stray K, von Schwedler U, Schinazi R, Preston B Antimicrob Agents Chemother. 1999; 43(8):2077-80.

PMID: 10428942 PMC: 89420. DOI: 10.1128/AAC.43.8.2077.


A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.

Smith R, Remington K, Preston B, Schinazi R, North T J Virol. 1998; 72(3):2335-40.

PMID: 9499094 PMC: 109533. DOI: 10.1128/JVI.72.3.2335-2340.1998.


A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Smith R, Remington K, Lloyd Jr R, Schinazi R, North T J Virol. 1997; 71(3):2357-62.

PMID: 9032372 PMC: 191345. DOI: 10.1128/JVI.71.3.2357-2362.1997.


Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Zhu Y, Remington K, North T Antimicrob Agents Chemother. 1996; 40(9):1983-7.

PMID: 8878567 PMC: 163459. DOI: 10.1128/AAC.40.9.1983.


References
1.
Pedersen N, Ho E, Brown M, Yamamoto J . Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 1987; 235(4790):790-3. DOI: 10.1126/science.3643650. View

2.
Mansuri M, Starrett Jr J, Ghazzouli I, Hitchcock M, Sterzycki R, Brankovan V . 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem. 1989; 32(2):461-6. DOI: 10.1021/jm00122a029. View

3.
Gardner M, Luciw P . Animal models of AIDS. FASEB J. 1989; 3(14):2593-606. DOI: 10.1096/fasebj.3.14.2556312. View

4.
Take Y, Inouye Y, Nakamura S, Allaudeen H, Kubo A . Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases. J Antibiot (Tokyo). 1989; 42(1):107-15. DOI: 10.7164/antibiotics.42.107. View

5.
Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View